327 related articles for article (PubMed ID: 16574205)
1. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
2. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.
Unger JB; Ivy JJ; Connor P; Charrier A; Ramaswamy MR; Ampil FL; Monsour RP
Gynecol Oncol; 2004 Jul; 94(1):212-6. PubMed ID: 15262145
[TBL] [Abstract][Full Text] [Related]
3. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
Brooks RA; Rader JS; Dehdashti F; Mutch DG; Powell MA; Thaker PH; Siegel BA; Grigsby PW
Gynecol Oncol; 2009 Jan; 112(1):104-9. PubMed ID: 18929403
[TBL] [Abstract][Full Text] [Related]
4. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study.
Chang TC; Law KS; Hong JH; Lai CH; Ng KK; Hsueh S; See LC; Chang YC; Tsai CS; Chou HH; Huang KG; Liou JD; Lin CT; Chao A; Chen MY; Wu TI; Ma SY; Yen TC
Cancer; 2004 Jul; 101(1):164-71. PubMed ID: 15222002
[TBL] [Abstract][Full Text] [Related]
6. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
7. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
10. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
12. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
[TBL] [Abstract][Full Text] [Related]
13. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
[TBL] [Abstract][Full Text] [Related]
14. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [
Shen WC; Chen SW; Wu KC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
Eur Radiol; 2019 Dec; 29(12):6741-6749. PubMed ID: 31134366
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
Chang WC; Hung YC; Lin CC; Shen YY; Kao CH
Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
[TBL] [Abstract][Full Text] [Related]
16. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
17. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
[TBL] [Abstract][Full Text] [Related]
18. The role of PET scanning in the detection of recurrent cervical cancer.
Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
[TBL] [Abstract][Full Text] [Related]
19. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET for management of cervical and ovarian cancer.
Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
